Search Results

Immunexpress, Pty Ltd. announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug Administration (FDA) for use with SeptiCyte RAPID®.

Immunexpress, Pty Ltd. announced a poster presentation by collaborators at University Hospitals Cleveland Medical Center at the 2023 American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Lab Expo that demonstrated the feasibility for quality improvement using SeptiCyte RAPID in patients suspected of sepsis.

Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today a poster presentation at the 2023 International Symposium on Intensive Care and Emergency Medicine.

Immunexpress, Pty Ltd. announced today a poster presentation at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) which evaluates the use of SeptiCyte® RAPID as a tool to determine sepsis status in patients admitted to the Intensive Care Unit (ICU).

Immunexpress, Pty Ltd. today announced the presentation of two posters evaluating SeptiCyte® RAPID at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) 2024, to take place from April 27 – 30 in Barcelona, Spain.

Immunexpress, Pty Ltd. announced today the launch of new SeptiCyte RAPID® EDTA blood compatible cartridges for the European market.

Immunexpress, Pty Ltd. today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted an International Classification of diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) code for Immunexpress’ host response molecular test for sepsis, SeptiCyte® RAPID.

Immunexpress, Pty Ltd. today announced that data validating the use of SeptiCyte® RAPID in differentiating sepsis from systemic inflammatory response syndrome (SIRS) was selected for presentation on Sunday, January 21, during the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress in Phoenix, Arizona, January 21 to 23, 2024.

Immunexpress, Pty Ltd. today announced a poster presentation validating the utility of SeptiCyte® RAPID in patients who are immunocompromised or are receiving immunosuppressive therapy at the Association for Molecular Pathology (AMP) 2023 Annual Meeting.

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced that Chief Executive Officer, Rolland Carlson, Ph.D., to present a corporate update, accessible on demand, at the virtual Biotech Showcase 2022 to be held Jan. 10-12 and Jan. 17–19, 2022.